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Response of parathyroid glands to calcitriol in culture: Is this metabolism [1]. Secondary HPT is characterized by high
response mediated by the genetic polymorphisms in vitamin D parathyroid hormone (PTH) levels and hyperplastic
receptor? parathyroid glands. Calcitriol is an important modulator
Background. Recently, we have developed a model of para-
of both PTH secretion and parathyroid cell proliferationthyroid tissue culture that allows the study of the response of
[2], and it is generally accepted that a deficiency ofthe parathyroid glands to long-term effectors, such as calcitriol,
calcitriol contributes to the development of parathyroidand that is also useful to study the likely effect of the genetic
polymorphisms in the functionality of the glands. The aim of hyperplasia [3]. Calcitriol acts through the vitamin D
this study was to evaluate the response to calcitriol of cultured receptor (VDR) in all of its target tissues. In the parathy-
parathyroid tissue from patients with secondary hyperparathy- roid glands, the calcitriol-VDR complex inhibits PTH
roidism (HPT) and the possible effect of vitamin D receptor
gene expression by binding to vitamin D–responsive ele-(VDR) gene polymorphisms on this response.
ments [4].Methods. Parathyroid glands (N 37) from 34 parathyroid-
ectomized patients (17 men, 17 women) were used. Several Several genetic polymorphisms have been described
gland fragments were cultured for 60 hours in the presence of in the VDR gene and certain alleles have been implicated
calcitriol 109 mol/L or 108 mol/L. DNA from each fragment in low bone mineral density (BMD) [5], risk of osteopo-
was extracted to normalize the hormone secretion levels and rotic fractures [6], and the tendency for hyperparathy-to genotype the restriction sites ApaI, BsmI, TaqI, and FokI
roidism [7].in the VDR gene.
In the last five years, several studies have examinedResults. The percentages of secretion observed in the re-
sponse to calcitriol were: 69% 28% (range, 3–100) and 46% the effect of VDR polymorphisms in the parathyroid
19% (range, 8–78) for calcitriol 109 mol/L and 108 mol/L, function, concentrating mainly on the relationship be-
respectively (P  0.004). None of the polymorphisms showed tween the prevalence of hyperparathyroidism (primary
statistical differences in response to calcitriol with any of the or secondary) and the allelic frequencies of VDR poly-concentrations used.
morphisms in different populations [8, 9]. However, onlyConclusion. Parathyroid glands cultured in vitro from pa-
a few studies have investigated the effect of VDR poly-tients with secondary HPT are able to respond to calcitriol
decreasing PTH synthesis. These results, however, do not sup- morphisms in the response to calcitriol [10, 11], none of
port the current hypothesis that VDR polymorphisms are in- them using parathyroid tissue cultured in vitro.
volved in the modulation of the parathyroid gland response. In the present study, a model of parathyroid tissue
culture developed recently in our laboratory that keeps
the parathyroid glands viable and functional for four
days (the period of time necessary to study the geneticMost patients with chronic renal failure who are un-
effect that calcitriol exerts on the parathyroid gland) hasdergoing hemodialysis develop secondary hyperparathy-
been used.roidism (HPT) due to abnormal calcium and phosphate
The aim of this study was to evaluate the response to
calcitriol by parathyroid glands taken from patients with
secondary HPT and cultured in vitro, and to evaluateKey words: secondary hyperparathyroidism, in vitro, parathyroid hor-
mone. the likely effect of the genetic polymorphisms in the
VDR gene on this response. 2003 by the International Society of Nephrology
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METHODS
The study was performed using 37 parathyroid gland
fragments from 34 patients (17 men, 17 women) with
secondary HPT who required parathyroidectomy.
Each gland fragment was cut into small fragments of
approximately 1 mm3, six of which were cultured for 60
hours at 37C in 2 mL of incubation medium containing
125 mmol/L NaCl, 5.9 mmol/L KCl, 1.2 mmol/L MgCl2,
1 mmol/L sodium piruvate, 4 mmol/L L-glutamine, 12
mmol/L glucose, 25 mmol/L sodium hepes, 1.2 mmol/L Fig. 1. Percentage of inhibition of the PTH secreted into the medium
by calcitriol used at two different concentrations (109 mol/L and 108CaCl2, 0.1 IU/mL insulin, 0.1% serum bovine albumin
mol/L). *P  0.004(BSA), 100 IU/mL penicillin, and 100 g/mL streptomy-
cin buffered at a pH of 7.4. Phosphorus was added as
NaH2PO4 and Na2HPO4 in a 1:2 proportion to achieve
a final phosphorus concentration of 1 mmol/L. Calcitriol gene, La Jolla, CA, USA). The samples were electropho-
was added directly to the plate wells at 109 mol/L or resed in a 2% agarose gel. The absence of the target site
108 mol/L. for the three endonucleases produced a single band of
Gland fragments were washed for eight hours with a 1365 bp (alleles B, A, and T for BsmI, ApaI, and TaqI,
two-hour renewal period, using fresh incubation me- respectively). The allele “b” (BsmI) produced two bands
dium, before the addition of the calcitriol. After the of 113 and 1252 bp, the allele “a” (ApaI) produced 284
washing period, calcitriol was added to four of the six and 1081 bp, and the allele “t” (TaqI) produced 208 and
fragments, but not to the other two (control groups). 1157 bp.
During the culture period the incubation medium was
changed every 12 hours. At the end of the experiment, Northern blot
the incubation medium was collected to determine the A method based on the extraction of RNA in one
iPTH secreted from three fragments (control, calcitriol step designed by Chomczynski [12] was used. RNA was
109 mol/L, and calcitriol 108 mol/L), while DNA was electrophoresed and then transferred to a nitrocellulose
extracted to normalize the secretion results and to geno- membrane. This membrane was hybridized with a spe-
type each patient for the different polymorphisms of the cific probe for human parathyroid hormone (PTH) and
VDR studied (FokI, BsmI, ApaI, and TaqI). RNA was the results were then normalized by comparison with
extracted from the other three fragments to determine the rRNA 28S levels.
the PTH expression by Northern blot.
VDR genotyping RESULTS
FokI polymorphism was detected by polymerase chain Thirty-seven fragments of parathyroid glands from pa-
reaction (PCR) and enzymatic digestion using the fol- tients with secondary HPT were cultured, but only 29
lowing primers (forward: CTCCGAAGGCACTGTGC fragments (taken from 26 patients, 13 men and 13 women)
TCA and reverse: AGAAGATACCACTCACCAAG were included in the study because the remaining glands
ACC) to amplify a region of 493 bp in the exon 2 of the did not respond to the treatment with calcitriol. The per-
VDR gene. PCR conditions were: 15 seconds at 95C, centage of glands (78%) able to respond to the calcitriol
15 seconds at 56C, and 40 seconds at 72C for 35 cycles. (N  29) were considered to be responders, while the
The PCR product was digested with the FokI restriction glands that did not respond to the calcitriol (22%) (N 8)
were considered to be nonresponders.enzyme (New England Biolabs, Beverly, MA, USA) and
electrophoresed in 2% agarose. The presence of the tar- The results show that parathyroid glands in culture
from the responders react to calcitriol in a dose-depen-get site produced two fragments of DNA of 191 and 302
bp (allele “f”). A fragment of 1365 bp of the VDR gene dent manner (Fig. 1). The percentages of inhibition of
PTH secretion observed with the two concentrations ofcontaining BsmI, ApaI, and TaqI target sites was then
amplified by PCR using the following primers: forward: calcitriol were: 31%  28% (range, 0–97) and 64% 
19% (range, 22–92) for 109 mol/L and 108 mol/L, re-GCAGAGTGTGCAGGCGATTCG and reverse: GTG
AAGCTCGTGTTCCCCGCAAT in the following PCR spectively (P  0.004). In addition, calcitriol was also
able to significantly inhibit iPTH synthesis in a dose-conditions: 30 seconds at 95C, 15 seconds at 64C, and
25 seconds at 72C for 35 cycles. The PCR product was dependent manner (Fig. 2). The observed percentages
of inhibition were: 38% and 52% for 109 mol/L anddivided into three different aliquots and digested with
the BsmI, ApaI, and TaqI restriction enzymes (Strata- 108 mol/L of calcitriol, respectively.
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Table 1. Genotype frequencies and the response of the glands for
each of the studied polymorphisms
109 mol/L 108 mol/L
Genotype and
frequency Mean  SD %
AA (18.2%) 6616 526
Aa 5127 3618(59.1%)
aa 6236 5518(22.7%)
BB 6616 526(14.3%)
Bb 5625 4122(64.3%)
bb 5831 5416(21.4%)
TT 4929 5215(34.8%)
Tt 5826 3921(52.2%)
Fig. 2. Percentage of inhibition in PTH synthesis (measured by North- tt 762 495(13.0%)
ern blot) by calcitriol used at two different concentrations (109 mol/L FF 5425 5021(33.3%)
and 108 mol/L). *P  0.007 Ff 6421 3815(59.3%)
ff 3220 5631(7.4%)
The control without calcitriol is considered to be 100%.
The genotype frequencies observed for the VDR poly-
morphisms were: 18.2%, 59.1%, and 22.7% for AA, Aa,
capable of responding to treatment, nor are they ableand aa, respectively; 14.3%, 64.3%, and 21.4% for BB,
to diminish PTH levels [17].Bb, and bb, respectively; 34.8%, 52.2%, and 13.0% for
Even using a concentration of calcitriol 10 times higherTT, Tt, and tt, respectively; and 33.3%, 59.3%, and 7.4%
than the highest peak reached in clinical treatments (108for FF, Ff, and ff, respectively. These genotype frequen-
mol/L), some of the glands (22%) did not respond to thecies (Table 1) were under Hardy-Weinberg equilibrium
calcitriol. This finding indicates that the concentration ofand revealed consistent values with those published in
calcitriol is not the only limiting factor and that the fail-the literature for Caucasian populations. There were no
ure in the response may be also due, as described bydifferences in the genotype frequencies between the pa-
other authors [18, 19], to the decrease in VDR levelstients with secondary HPT and a nonselected population
that occurs in hyperplasic parathyroid glands.of 317 people from our home (data not shown).
However, the remaining 78% of cultured glands re-None of the polymorphisms showed statistical differ-
sponded to the calcitriol that was added to the incubationences between their genotypes in the response of the
medium, and although the percentage of inhibition byglands to calcitriol with any of the concentrations used
calcitriol was rather high among the glands, they re-
(Table 1). No differences were found if nonresponders
sponded in a dose-dependent manner.
were included, and none of the genotypes were over- The model of culture used also allows us to study the
represented or lowly represented in the nonresponders. effect of VDR polymorphisms on the response of the
Unexpectedly, TT and ff genotypes showed a higher glands to calcitriol, keeping other variables implicated
response to 109 mol/L than to 108 mol/L of calcitriol, in the modulation of the parathyroid gland, such as cal-
but did not achieve statistical significance. cium and phosphate, under control. In previous studies
done in vivo [10, 11], these variables could mask the
likely effect of the VDR polymorphisms on parathyroidDISCUSSION
gland physiology.
Recently, we have developed a new model of para- No differences were found in the distribution of the
thyroid tissue culture that maintains the viability and genotype frequencies between our patients and other
functionality of the glands for up to four days; thus, control populations, as other authors have described
the response of the gland to long-term effectors such as [20–22]. However, Carling et al [23, 24] found a higher
calcitriol can be studied [13]. The tissue culture models presence of the baT haplotype, or bb, aa, and TT geno-
used in the description of our methods maintained the types in patients with primary hyperparathyroidism. Na-
glands cultured in vitro for up to 24 hours only [14]. gaba et al [25] and Yokoyama et al [9] found higher
Parathyroid glands from patients with secondary HPT PTH levels in patients in hemodialysis in presence of
that required parathyroidectomy were used after being the bb genotype and the aa genotype, respectively. Nev-
cultured with two different concentrations of calcitriol ertheless, the Caucasian population cannot be compared
109 mol/L and 108 mol/L. A concentration of 109 mol/L with the Japanese populations because the genotype dis-
is equivalent to the maximum calcitriol peak reached by tributions are quite different (the BB genotype is almost
patients undergoing vitamin D therapy [15, 16]. Between absent in Oriental populations [26]).
20% to 25% of patients with secondary HPT caused by Similarly, no differences were found in the response
to calcitriol of the parathyroid glands according to thechronic renal failure and treated with calcitriol are neither
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levels correspond to polymorphic VDR alleles in human parathy-genotypes with any of the concentrations used. The dif-
roid tumors. J Clin Endocrinol Metab 83:2255–2259, 1998
ferences observed in the response of each one of the 9. Yokoyama K, Shigematsu T, Tsukada T, et al: Apa I polymor-
phism in the vitamin D receptor gene may affect the parathyroidgenotypes to the two concentrations of calcitriol used
response in Japanese with end-stage renal disease. Kidney Intachieved statistical significance in some cases, but not in 53:454–458, 1998
all. Unexpectedly, TT and ff genotypes showed a higher 10. Howard G, Nguyen T, Morrison N, et al: Genetic influences on
bone density: Physiological correlates of vitamin D receptor generesponse to 109 mol/L than to 108 mol/L of calcitriol,
alleles in premenopausal women. J Clin Endocrinol Metab 80:2800–but without statistical significance. 2805, 1995
11. Marco MP, Martinez I, Betriu A, et al: Influence of BsmI vitaminThese results seem to indicate that the VDR genetic
D receptor gene polymorphism on the response to a single boluspolymorphisms in ApaI, BsmI, TaqI, and FokI cannot
of calcitrol in hemodialysis patients. Clin Nephrol 56:111–116, 2001
explain the different responses observed in our popula- 12. Chomczynski P: A reagent for the single-step simultaneous isola-
tion of RNA, DNA and proteins from cell and tissue samples.tion between the glands and do not support the hypothe-
Biotechniques 15:532–534, 536–537, 1993sis that VDR polymorphisms are relevant factors in the 13. Naves Diaz M, Menarguez J, Santamaria I, et al: Long-term
modulation of the parathyroid gland response. study of functionally and viability of rat and human parathyroid
glands. J Am Soc Nephrol 12:769A, 2001
14. Canalejo A, Almaden Y, Torregrosa V, et al: The in vitro effect
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